Public disclosures

Mulroy Michael H.

Company insiders · Director · Lineage Cell Therapeutics, Inc.

Advertisement
FollowLatest SEC filingSEC filer historyProfile details as reported on 2026-11-19.Following & alerts
Reported transaction lines
1
Buy lines
1
Sell lines
0

Filing activity by month

Original filing lines in up to 12 months with activity.

  • 2026-111

Frequently disclosed stocks

Disclosure history

More filters
Clear filters
Reporting investorSecurityActivityTransaction / periodFiledReported amountSource
Mulroy Michael H.

Director · Lineage Cell Therapeutics, Inc.

LCTX

Lineage Cell Therapeutics, Inc.

Buy
Filing details

SEC transaction code P

Common Shares · Direct ownership · Reported balance after transaction: 328555 · SEC code covers open-market or private transactions · The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8656 to $0.8755 inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within theranges set forth in this footnote 1.

2026-11-172026-11-19

≈ $26,100.00

30,000 shares/units

SEC 4

Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.

Advertisement